Yunxin Zeng

Shenzhen, 518000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications

Clinical outcomes and molecular features of CEBPA-mutated MPAL: a multi-center case series.

Clinical outcomes and molecular features of CEBPA-mutated MPAL: a multi-center case series.

Journal: Experimental hematology & oncology
Published: May 31, 2026

LSP1 is a prognostic biomarker associated with apoptosis in acute myeloid leukemia.

LSP1 is a prognostic biomarker associated with apoptosis in acute myeloid leukemia.

Journal: Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
Published: December 10, 2025

MICA gene modulates immune microenvironment and comorbid mechanisms in diffuse large B-cell lymphoma and primary Sjögren's syndrome.

MICA gene modulates immune microenvironment and comorbid mechanisms in diffuse large B-cell lymphoma and primary Sjögren's syndrome.

Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: September 30, 2025

Sustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation.

Sustained IL-15 release enhances CAR-T therapy in multiple myeloma via FOXO1 signaling axis activation.

Journal: Biomaterials
Published: September 24, 2025

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration.

Inhibition of CRM1 reverses hypoxia-driven chemoresistance in acute myeloid leukemia via overcoming HIF-1α-mediated lysosomal sequestration.

Journal: Frontiers in immunology
Published: September 22, 2025

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Journal: Biomarker research
Published: June 24, 2025

Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study.

Treatment outcomes of zanubrutinib-based regimen in newly diagnosed patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma: a retrospective multicenter real-world study.

Journal: Annals of hematology
Published: May 07, 2025

Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study.

Romiplostim versus Recombinant human thrombopoietin in umbilical cord blood transplantation: a single-center retrospective study.

Journal: Annals of hematology
Published: February 27, 2025

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

Journal: The Lancet regional health. Western Pacific
Published: February 26, 2025

Aclacinomycin enhances the killing effect of allogeneic NK cells on acute myeloid leukemia cells by inducing immunogenic cell death.

Aclacinomycin enhances the killing effect of allogeneic NK cells on acute myeloid leukemia cells by inducing immunogenic cell death.

Journal: Frontiers in immunology
Published: November 03, 2024

Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study.

Intensified conditioning containing decitabine versus standard myeloablative conditioning for adult patients with KMT2A-rearranged leukemia: a multicenter retrospective study.

Journal: BMC medicine
Published: July 25, 2024

Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma.

Natural killer cell-associated prognosis model characterizes immune landscape and treatment efficacy of diffuse large B cell lymphoma.

Journal: Cytokine
Published: June 25, 2024
Showing 1-12 of 26

Last Updated: 09/26/2026